Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Charles N Pegram

Showing results (1-10 of 13) with videos related to

Pageof 2
Sort By:
Journal of Immunological Methods|December 28, 2016
Development and validation of a cell-based fluorescent method for measuring antibody affinityXin Yu, Charles N Pegram, Darell D Bigner, et al.
Nuclear Medicine and Biology|March 19, 2004
Human/murine chimeric 81C6 F(ab')(2) fragment: preclinical evaluation of a potential construct for the targeted radiotherapy of malignant gliomaAbraham Boskovitz, Gamal H Akabani, Charles N Pegram, et al.
Applied Microbiology and Biotechnology|December 26, 2016
Production and quality control assessment of a GLP-grade immunotoxin, D2C7-(scdsFv)-PE38KDEL, for a phase I/II clinical trialVidyalakshmi Chandramohan, Charles N Pegram, Hailan Piao, et al.
Mabs|August 9, 2013
Affinity-matured recombinant immunotoxin targeting gangliosides 3'-isoLM1 and 3',6'-isoLD1 on malignant gliomasHailan Piao, Chien-Tsun Kuan, Vidya Chandramohan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 17, 2013
Construction of an immunotoxin, D2C7-(scdsFv)-PE38KDEL, targeting EGFRwt and EGFRvIII for brain tumor therapyVidyalakshmi Chandramohan, Xuhui Bao, Stephen T Keir, et al.
BMC Cancer|September 3, 2010
MRP3: a molecular target for human glioblastoma multiforme immunotherapyChien-Tsun Kuan, Kenji Wakiya, James E Herndon, et al.
Nuclear Medicine and Biology|October 1, 2011
Radioimmunotargeting of malignant glioma by monoclonal antibody D2C7 reactive against both wild-type and variant III mutant epidermal growth factor receptorsMichael R Zalutsky, Abraham Boskovitz, Chien-Tsun Kuan, et al.
Blood|April 22, 2004
Phase 1 trial study of 131I-labeled chimeric 81C6 monoclonal antibody for the treatment of patients with non-Hodgkin lymphomaDavid A Rizzieri, Gamal Akabani, Michael R Zalutsky, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|June 7, 2005
Dosimetry and radiographic analysis of 131I-labeled anti-tenascin 81C6 murine monoclonal antibody in newly diagnosed patients with malignant gliomas: a phase II studyGamal Akabani, David A Reardon, R Edward Coleman, et al.
Neuro-Oncology|February 22, 2008
A pilot study: 131I-antitenascin monoclonal antibody 81c6 to deliver a 44-Gy resection cavity boostDavid A Reardon, Michael R Zalutsky, Gamal Akabani, et al.
Pageof 2

Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
Journal of Immunological Methods|December 28, 2016
Development and validation of a cell-based fluorescent method for measuring antibody affinityXin Yu, Charles N Pegram, Darell D Bigner, et al.
Nuclear Medicine and Biology|March 19, 2004
Human/murine chimeric 81C6 F(ab')(2) fragment: preclinical evaluation of a potential construct for the targeted radiotherapy of malignant gliomaAbraham Boskovitz, Gamal H Akabani, Charles N Pegram, et al.
Applied Microbiology and Biotechnology|December 26, 2016
Production and quality control assessment of a GLP-grade immunotoxin, D2C7-(scdsFv)-PE38KDEL, for a phase I/II clinical trialVidyalakshmi Chandramohan, Charles N Pegram, Hailan Piao, et al.
Mabs|August 9, 2013
Affinity-matured recombinant immunotoxin targeting gangliosides 3'-isoLM1 and 3',6'-isoLD1 on malignant gliomasHailan Piao, Chien-Tsun Kuan, Vidya Chandramohan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 17, 2013
Construction of an immunotoxin, D2C7-(scdsFv)-PE38KDEL, targeting EGFRwt and EGFRvIII for brain tumor therapyVidyalakshmi Chandramohan, Xuhui Bao, Stephen T Keir, et al.
BMC Cancer|September 3, 2010
MRP3: a molecular target for human glioblastoma multiforme immunotherapyChien-Tsun Kuan, Kenji Wakiya, James E Herndon, et al.
Nuclear Medicine and Biology|October 1, 2011
Radioimmunotargeting of malignant glioma by monoclonal antibody D2C7 reactive against both wild-type and variant III mutant epidermal growth factor receptorsMichael R Zalutsky, Abraham Boskovitz, Chien-Tsun Kuan, et al.
Blood|April 22, 2004
Phase 1 trial study of 131I-labeled chimeric 81C6 monoclonal antibody for the treatment of patients with non-Hodgkin lymphomaDavid A Rizzieri, Gamal Akabani, Michael R Zalutsky, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|June 7, 2005
Dosimetry and radiographic analysis of 131I-labeled anti-tenascin 81C6 murine monoclonal antibody in newly diagnosed patients with malignant gliomas: a phase II studyGamal Akabani, David A Reardon, R Edward Coleman, et al.
Neuro-Oncology|February 22, 2008
A pilot study: 131I-antitenascin monoclonal antibody 81c6 to deliver a 44-Gy resection cavity boostDavid A Reardon, Michael R Zalutsky, Gamal Akabani, et al.
Pageof 2